Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in ...

Men with prostate cancer that returns after surgery or radiation and are left with few options could benefit from a new treatment.

A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer, reducing death risk by over 40%. The study followed more than 1,000 ...

BERLIN -- Combining enzalutamide (Xtandi) with androgen deprivation therapy (ADT) significantly improved overall survival (OS ...

Drugs already in use could be combined to form a two-pronged attack on advanced prostate cancer, a study suggests.

The 2025 ESMO annual meeting featured a prostate cancer session and a presentation by Dr. Alicia K. Morgans discussing ...

Men with genes that increase the risk of prostate cancer should have annual checks from the age of 40, research has shown.

(UroToday.com) The 2025 European Society of Medical Oncology (ESMO) Annual Congress held in Berlin, Germany between September 17 th and 21 st was host to the session Mini oral session: GU tumours, ...

The travel writer and host of 'Rick Steves Europe' shares an update after prostate cancer diagnosis to encourage men to 'say ...

Follow-up overall survival, months, median (range) 96 (15-120) Follow-up PSA to recurrence or death, months, median (range) 55 (11-111) Follow-up PSA patients alive and recurrence-free, months, median ...

My doctor was of the opinion that over-medicalisation of patients was a common problem, and that a high PSA reading might ...

Sponsored: Prostate cancer will affect about 1 in 8 men in their lifetime. Yet, data from the Prostate Cancer Foundation (PCF ...